Pharma BD Deal Intelligence
JPMorgan's Michael Weinstein called Trauson 'highly profitable with gross margins in the high 60 percent range' and 'the largest distributor of trauma products…
Piper Jaffray analyst Matt Miksic viewed the China middle market as an attractive opportunity, saying the Trauson acquisition nicely complements Stryker's…
China's trauma implants market reached 3.8B RMB in 2013 (CAGR 17.6% since 2009) and spine reached 3.3B RMB (CAGR 18.7%); the broader orthopedic instrument…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Stryker offered HK$7.50/share cash (total $764M, EV ~$685M) for Chinese orthopedics maker Trauson; expanded China/EM footprint in trauma and spine.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Stryker Corporation / Trauson Holdings Company Limited (this deal) | 2013 | $764M | 37 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Stryker Corporation / Wright Medical Group N.V. | 2019 | $5.4B | 81 |
| Stryker Corporation / Gaymar Industries | 2010 | $150M | 54 |
| Stryker Corporation / Inari Medical, Inc. | 2025 | $4.9B | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Stryker Corporation deals · Other deals